SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 365: 16871717.
  • 2
    Buzdar AU, Jonat W, Howell A, et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer. 1998; 83: 11421152.
  • 3
    Kaufmann M, Bajetta E, Dirix LY, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol. 2000; 18: 13991411.
  • 4
    Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol. 1998; 16: 453461.
  • 5
    Buzdar A, Douma J, Davidson N, et al. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol. 2001; 19: 33573366.
  • 6
    Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol. 2001; 19: 25962606.
  • 7
    Nabholtz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol. 2000; 18: 37583767.
  • 8
    Bonneterre J, Thurlimann B, Robertson JF, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol. 2000; 18: 37483757.
  • 9
    Paridaens R, Dirix L, Lohrisch C, et al. Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol. 2003; 14: 13911398.
  • 10
    Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005; 365: 6062.
  • 11
    Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005; 353: 27472757.
  • 12
    Jonat W, Gnant M, Boccardo F, et al. Switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-responsive early breast cancer: a meta-analysis of the ARNO 95 trial, ABCSG Trial 8, and the ITA trial. San Antonio Breast Cancer Symp. 2005: 18. Abstract 2073.
  • 13
    Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004: 350: 10811092.
  • 14
    Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005; 97: 12621271.
  • 15
    Carlson RW, Hudis CA, Pritchard KI. Adjuvant endocrine therapy in hormone receptor-positive postmenopausal breast cancer: evolution of NCCN, ASCO, and St Gallen recommendations. J Natl Compr Cancer Network. 2006; 4: 971979.
  • 16
    de Mascarel I, Bonichon F, Durand M, et al. Obvious peritumoral emboli: an elusive prognostic factor reappraised. Multivariate analysis of 1320 node-negative breast cancers. Eur J Cancer. 1998; 34: 5865.
  • 17
    de Mascarel I, Bonichon F, Coindre JM, et al. Prognostic significance of breast cancer axillary lymph node micrometastases assessed by two special techniques: reevaluation with longer follow-up. Br J Cancer. 1992; 66: 523527.
  • 18
    Ryden L, Jirstrom K, Bendahl PO, et al. Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer. J Clin Oncol. 2005; 23: 46954704.
  • 19
    McShane LM, Altman DG, Sauerbrei W, et al. REporting recommendations for tumour MARKer prognostic studies (REMARK). J Natl Cancer Inst. 2005; 97: 11801184.
  • 20
    Albain K, Barlow W, O'Malley F, et al. Concurrent (CAFT) versus sequential (CAF-T) chemohormonal therapy (cyclophosphamide, doxorubicin, 5-fluorouracil, tamoxifen) versus T alone for postmenopausal, node-positive, estrogen (ER) and/or progesterone (PgR) receptor-positive breast cancer: mature outcomes and new biologic correlates on phase III intergroup trial 0100 (SWOG-8814). San Antonio Breast Cancer Symp. 2004. Abstract 37.
  • 21
    Wils JA, Bliss JM, Coombes MG, et al. Epirubicin plus tamoxifen versus tamoxifen alone in node-positive post menopausal patients with breast cancer: a randomized trial of the International Collaborative Cancer Group. J Clin Oncol. 1999; 17: 19881998.
  • 22
    Fargeot P, Bonneterre J, Roche H, et al. Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French Adjuvant Study Group 08 trial. J Clin Oncol. 2004; 22: 46224630.
  • 23
    Namer M, Fargeot P, Roche H, et al. Improved disease-free survival with epirubicin-based chemoendocrine adjuvant therapy compared with tamoxifen alone in one to three node-positive, estrogen-receptor-positive, postmenopausal breast cancer patients: results of French Adjuvant Study Group 02 and 07 trials. Ann Oncol. 2006; 17: 6573.
  • 24
    Hery M, Delozier T, Ramaioli A, et al. Natural history of node-negative breast cancer: are conventional prognostic factors predictors of time to relapse? Breast. 2002; 11: 442448.
  • 25
    Kollias J, Murphy CA, Elston CW, et al. The prognosis of small primary breast cancers. Eur J Cancer. 1999; 35: 908912.
  • 26
    Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol. 1996; 14: 27382746.
  • 27
    Hilsenbeck FG, Ravdin PM, de Moor CA, et al. Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat. 1998; 52: 227237.
  • 28
    Arriagada R, Le MG, Dunant A, et al. Twenty-five years of follow-up in patients with operable breast carcinoma: correlation between clinicopathologic factors and the risk of death in each 5-year period. Cancer. 2006; 106: 743750.
  • 29
    Osborne CK, Schiff R, Arpino G, et al. Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapy. Breast. 2005; 14: 458465.
  • 30
    Dowsett M, Cuzick J, Wale C, et al. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J Clin Oncol. 2005; 23: 75127517.
  • 31
    Harris AL, Nicholson S, Sainsbury JR, et al. Epidermal growth factor receptors in breast cancer: association with early relapse and death, poor response to hormones and interactions with neu. J Steroid Biochem. 1989; 34: 123131.
  • 32
    Wright C, Nicholson S, Angus B, et al. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer. 1992; 65: 118121.
  • 33
    De Laurentiis M, Arpino G, Massarelli E, et al. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res. 2005; 11: 47414748.
  • 34
    Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1 and/or ErbB-2 positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol. 2001; 19: 38083816.
  • 35
    Smith IE, Dowsett M, Ebbs SR, et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol. 2005; 23: 51085116.
  • 36
    Jin Y, Desta Z, Stearns V, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst. 2005; 97: 3039.
  • 37
    Goetz MP, Knox SK, Suman VJ, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat. 2007; 101: 113121.
  • 38
    Cuzick J, Sasieni P, Howell A. Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen? Br J Cancer. 2006; 94: 460464.
  • 39
    Punglia RS, Kuntz KM, Winer EP, et al. Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis. J Clin Oncol. 2005; 23: 51785187.
  • 40
    Punglia RS, Kuntz KM, Winer EP, et al. The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis. Cancer. 2006; 106: 25762582.
  • 41
    Asmar L, Cantrell J, Vukelja SJ, et al. Final analysis of a planned comparison of menopausal symptoms in 1618 patients receiving either exemestane (E) or tamoxifen (T) in a blinded adjuvant hormonal study. San Antonio Breast Cancer Symp. 2005. Abstract 2039.
  • 42
    Fallowfield L, Cella D, Cuzick J, et al. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. J Clin Oncol. 2004; 22: 42614271.
  • 43
    Enjuanes A, Garcia-Giralt N, Supervia A, et al. Functional analysis of the I.3, I.6, pII and I.4 promoters of CYP19 (aromatase) gene in human osteoblasts and their role in vitamin D and dexamethasone stimulation. Eur J Endocrinol. 2005; 153: 981988.
  • 44
    Jenkins V, Shilling V, Fallowfield L, et al. Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. Psychooncology. 2004; 13: 6166.
  • 45
    Lonning PE. Comparing cost/utility of giving an aromatase inhibitor as monotherapy for 5 years versus sequential administration following 2–3 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast cancer. Ann Oncol. 2006; 17: 217225.
  • 46
    Younis T, Rayson D, Dewar R, et al. Modeling for cost-effective-adjuvant aromatase inhibitor strategies for postmenopausal women with breast cancer. Ann Oncol. 2007; 18: 293298.
  • 47
    McArthur HL, Olivotto I, Gelmon KA, et al. Risk of early relapse in post-menopausal women with early stage, estrogen receptor positive (ER+) breast cancer on tamoxifen. San Antonio Breast Cancer Symp. 2005. Abstract 3001.
  • 48
    Mauriac L, Keshaviah A, Debled M, et al. Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG-1-98 trial. Ann Oncol. In press.
  • 49
    Chagpar AB, Mcmasters KM, Martin RC, et al. Determinants of early distant metastatic disease in elderly patients with breast cancer. Am J Surg. 2006; 192: 317321.